Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with high postoperative recurrence rates and poor prognosis. Mitotane remains the only approved agent for ACC, exerting antitumor effects by disrupting mitochondrial integrity, inhibiting steroidogenic enzymes, and interfering with cholesterol metabolism.